Vertex Pharma to seek quick FDA approval for kidney disease drug, acquired for $4.9B

Povetacicept, an immunology drug from Vertex Pharmaceuticals designed to block two targets, achieved the primary goal of a Phase 3 clinical trial for the rare kidney disease immunoglobulin A nephropathy. The fusion protein comes from Alpine Immune Sciences, which Vertex acquired, and analysts say the drug has best-in-class potential.

The post Vertex Pharma seeks quick FDA approval for kidney disease drug acquired for $4.9B appeared first on MedCity News.